These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36555350)

  • 1. Plasma Calprotectin Levels Associate with Suspected Metabolic-Associated Fatty Liver Disease and All-Cause Mortality in the General Population.
    Bourgonje AR; van den Berg EH; Kieneker LM; Nilsen T; Hidden C; Bakker SJL; Blokzijl H; Dullaart RPF; van Goor H; Abdulle AE
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative stress is associated with suspected non-alcoholic fatty liver disease and all-cause mortality in the general population.
    Damba T; Bourgonje AR; Abdulle AE; Pasch A; Sydor S; van den Berg EH; Gansevoort RT; Bakker SJL; Blokzijl H; Dullaart RPF; van Goor H; Moshage H
    Liver Int; 2020 Sep; 40(9):2148-2159. PubMed ID: 32558346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
    Capela TL; Silva VM; Freitas M; Arieira C; Gonçalves TC; de Castro FD; Magalhães J; Cotter J
    BMC Gastroenterol; 2023 Dec; 23(1):437. PubMed ID: 38093213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities.
    Okada A; Yamada G; Kimura T; Hagiwara Y; Yamaguchi S; Kurakawa KI; Nangaku M; Yamauchi T; Matsuyama Y; Kadowaki T
    J Diabetes Investig; 2023 Mar; 14(3):463-478. PubMed ID: 36566480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang.
    Guo Y; Hu Y; Yang J; Ma R; Zhang X; Guo H; Wang X; Li Y; Peng X; Zhang S; He J; Guo S
    Eur J Med Res; 2023 Dec; 28(1):555. PubMed ID: 38042816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes.
    Wang C; Cai Z; Deng X; Li H; Zhao Z; Guo C; Zhang P; Li L; Gu T; Yang L; Zhao L; Wang D; Yuan G
    Int J Med Sci; 2021; 18(14):3280-3289. PubMed ID: 34400897
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma Calprotectin Levels Associate With New-Onset Hypertension in the General Population: A Prospective Cohort Study.
    Bourgonje AR; Bourgonje MF; la Bastide-van Gemert S; Nilsen T; Hidden C; Gansevoort RT; Bakker SJL; Mulder DJ; Dullaart RPF; Abdulle AE; van Goor H
    J Am Heart Assoc; 2024 Jan; 13(1):e031458. PubMed ID: 38156449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
    Hu Q; Chen Y; Bao T; Huang Y
    Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study.
    Liu Y; Liu S; Huang J; Zhu Y; Lin S
    J Gastroenterol Hepatol; 2022 May; 37(5):938-945. PubMed ID: 35174539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study.
    van den Berg EH; Gruppen EG; Blokzijl H; Bakker SJL; Dullaart RPF
    J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers.
    Theofilis P; Vordoni A; Tsimihodimos V; Kalaitzidis RG
    High Blood Press Cardiovasc Prev; 2023 Jan; 30(1):63-72. PubMed ID: 36626077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction and Validation of Metabolic Dysfunction-Associated Fatty Liver Disease Using Fatty Liver-Related Indices in a Japanese Population.
    Moriyama K
    Metab Syndr Relat Disord; 2024 Apr; 22(3):190-198. PubMed ID: 38153394
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma Calprotectin and New-onset Type 2 Diabetes in the General Population: A Prospective Cohort Study.
    Bourgonje AR; Bourgonje MF; Sokooti S; la Bastide-van Gemert S; Nilsen T; Hidden C; Gansevoort RT; Mulder DJ; Hillebrands JL; Bakker SJL; van Beek AP; Dullaart RPF; van Goor H; Abdulle AE
    J Clin Endocrinol Metab; 2024 Dec; 110(1):e150-e159. PubMed ID: 38436468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals.
    Tanaka M; Takahashi S; Higashiura Y; Sakai A; Koyama M; Saitoh S; Shimamoto K; Ohnishi H; Furuhashi M
    J Diabetes Investig; 2022 May; 13(5):878-888. PubMed ID: 34889064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study.
    Mayén AL; Sabra M; Aglago EK; Perlemuter G; Voican C; Ramos I; Debras C; Blanco J; Viallon V; Ferrari P; Olsen A; Tjønneland A; Langmann F; Dahm CC; Rothwell J; Laouali N; Marques C; Schulze MB; Katzke V; Kaaks R; Palli D; Macciotta A; Panico S; Tumino R; Agnoli C; Farràs M; Molina-Montes E; Amiano P; Chirlaque MD; Castilla J; Werner M; Bodén S; Heath AK; Tsilidis K; Aune D; Weiderpass E; Freisling H; Gunter MJ; Jenab M
    BMC Med; 2024 Jun; 22(1):221. PubMed ID: 38825687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017-2018.
    Yang Z; Gong D; He X; Huang F; Sun Y; Hu Q
    Front Nutr; 2023; 10():1113789. PubMed ID: 36860686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses.
    Mori K; Tanaka M; Hosaka I; Mikami T; Endo K; Hanawa N; Ohnishi H; Furuhashi M
    Hypertens Res; 2023 May; 46(5):1110-1121. PubMed ID: 36717630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Performance of Biomarker-Based Scores as Predictors of Metabolic Dysfunction-Associated Fatty Liver Disease Risk in Healthy Children.
    Bergmann K; Stefanska A; Krintus M; Szternel L; Bilinski WJ; Paradowski PT; Sypniewska G
    Nutrients; 2023 Aug; 15(16):. PubMed ID: 37630857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.